Articles By Trisha Gladd

51. Merck Assesses Single Use: Does It Make Sense At A Large Scale? 5/14/2014

    In an industry as conservative as the pharmaceutical industry, it is common practice to be adverse to new technologies because they are often viewed as too much of a risk. However, in this effort to play it safe, companies force themselves into a repetitive state of employing technologies that may not be the most efficient or effective. Rather than getting stuck in old habits — or conversely, jumping too quickly into new ones — Merck has put together a group of teams it calls the Technology Encouragement Collaborators, or TEC, to look at new technologies and determine whether or not to implement them.

52. BDP Week Highlights The Importance Of Communication In BioPharma 4/4/2014

    At this year’s Biopharmaceutical Development and Production (BDP) Week, March 24-27 at the Hilton Bayfront Hotel, I attended several sessions that focused on how to strengthen the relationship between partners in the pharmaceutical industry. One overwhelming theme in each presentation was the importance of communicating effectively and clearly with everyone involved in a project.

53. Where Do Ideas Come From? Time Is Money, So Spend It Wisely 4/3/2014

    In a traditional office environment, hours upon hours are often spent collaborating with other people to come up with game-changing ideas. Even the time spent alone at your desk can be occupied with juggling multiple responsibilities and tasks. It’s usually only during downtime at the end of the day, whether it’s a quiet ride home in the car or lying in bed at night, that we allow ourselves time to relax and reflect. Tony and Oliver Stauffer, president and chief operating officer at Packaging Technology & Inspections, as well as father and son, believe it’s during these moments to ourselves that we have the ability to come up with some of our best ideas.

54. Pfizer Collaboration Prepares For The Future Of Flexible Manufacturing 11/20/2013

    With the landscape of the industry shifting toward the need for more flexibility, pharma companies are exploring more ways to keep pace with this demand while still keeping costs low. In a recent announcement, GEA Process Engineering, G-CON Manufacturing, and Pfizer revealed how they’re addressing this challenge — a Portable Continuous Miniature & Modular (PCMM) manufacturing collaboration.

55. Gaining Efficiency Through Faster Integration of Single-Use Products 9/24/2013

    Considered a full-service integrator of products in the biopharmaceutical industry, Saint-Gobain offers an online platform that improves their efficiencies to design single-use products by creating a 3-dimensional product drawing.

56. Analytical QbD at Teva: Knowledge Is Power Only When You Share It

    Rosario LoBrutto, is currently Senior Director, Head of Development Parenterals at Teva. Throughout his career he has designed, coordinated, and implemented QbD programs and provided risk management trainings to product development units (quality, analytical, formulation, process chemists), and quality control, regulatory, and operations units. He understands the value of risk assessment and strategy for proactive failure reduction as opposed to reactive trouble shooting. In his interpretation of the ICH Harmonised Tripartite Guideline for Pharmaceutical Development Q9, a guidance document for QbD, LoBrutto breaks the QbD process down into three phases of risk facilitation as it relates to analytics.

57. Meet The Board: Pfizer's Dr. Firelli Alonso-Caplen Discusses Outsourcing Challenges And The Future Of Single Use

    I recently spoke with one of Bioprocess Online's Editorial Board members, Dr. Firelli Alonso-Caplen, Senior Director, BioTherapeutics & Vaccines Outsourcing at Pfizer, about the challenges she faces in her role and where she sees the future of single-use technology.